Andra AP fonden Invests $178,000 in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Andra AP fonden acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 400 shares of the medical equipment provider’s stock, valued at approximately $178,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. One Wealth Management Investment & Advisory Services LLC raised its position in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 23 shares during the period. Indiana Trust & Investment Management CO raised its holdings in Intuitive Surgical by 5.3% during the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares during the period. Hoxton Planning & Management LLC lifted its position in shares of Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 25 shares in the last quarter. First Affirmative Financial Network boosted its holdings in shares of Intuitive Surgical by 2.7% in the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after acquiring an additional 26 shares during the period. Finally, Advance Capital Management Inc. grew its position in shares of Intuitive Surgical by 3.8% in the first quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after purchasing an additional 27 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their target price for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Robert W. Baird raised their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. Morgan Stanley upped their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target for the company. Finally, Barclays upped their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Trading Up 0.6 %

Shares of NASDAQ ISRG opened at $494.01 on Friday. The stock has a market cap of $175.23 billion, a price-to-earnings ratio of 89.17, a P/E/G ratio of 5.20 and a beta of 1.39. The stock’s 50-day moving average is $462.82 and its 200 day moving average is $420.84. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $494.15.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the firm posted $1.18 earnings per share. The business’s revenue was up 14.5% compared to the same quarter last year. On average, analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,458,979.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,458,979.60. The disclosure for this sale can be found here. Insiders sold 50,555 shares of company stock valued at $24,267,737 over the last three months. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.